2023 Living Legends in Psychopharmacology: CE Conference

LIVING LEGENDS IN PSYCHOPHARMACOLOGY: FROM CURRENT EVIDENCE BASE TO ADVANCES IN TREATMENT

MARCH 31APRIL 1, 2023

FAIRMONT COPLEY PLAZA, BOSTON, MASS.

Course Directors and Co-moderators

Barbara Coffey, M.D., M.S.

Charles Nemeroff, M.D., Ph.D.

Faculty

Barbara Coffey, M.D., M.S.

Charles Nemeroff, M.D., Ph.D.

Ross Baldessarini, M.D., D.Sc. (hon)

Elizabeth Crocco, M.D.

Ariadna Forray, M.D.

Philip Harvey, Ph.D.

Sogol Javaheri, M.D.

Martin Samuels, M.D., D.Sc. (hon)

Alan Schatzberg, M.D.

David Sheehan, M.D., M.B.A.

Stephen Stahl, M.D., Ph.D., D.Sc. (hon)

Daniel Weinberger, M.D.

Roger Weiss, M.D.

Sponsored by the University of Miami Miller School of Medicine Department of Psychiatry and Behavioral Sciences

Legendary faculty

Present and emerging treatments for schizophrenia and bipolar disorder

Bipolar depression

Treatment-resistant depression

Psychedelics and ketamine

TMS and ECT

Psychopharmacologic treatment of anxiety spectrum and sleep disorders

PTSD

Interface of psychiatry with neurology and medicine

Psychopharmacology of alcohol and substance abuse disorders

Psychopharmacologic treatment of women's mental health issues

Child, adolescent, and geriatric psychopharmacology

COURSE DESCRIPTION

The University of Miami Leonard M. Miller School of Medicine Department of Psychiatry and Behavioral Sciences invites you to attend an exciting new conference, titled Living Legends in Psychopharmacology targeted for the practicing clinician. Lectures will center on treatment of usual psychiatric patients with emphasis on those who are difficult to treat or are treatment resistant. Newer treatments and developing treatment strategies will be discussed, including recommended algorithms, treatment sequencing, and targeted combined pharmacotherapy.

It is recommended that course attendees have some familiarity with the neurobiological and genetic contributions to psychiatric illnesses as well as an understanding of the basic therapeutic mechanisms of psychotropic medications. This conference will emphasize the topics most relevant to current clinical practice. Updates on genetic contributions to psychopathology will serve as a foundation for discussion of specific psychiatric symptoms and disorders. Understanding of the interface between psychiatric, neurological, and medical illness, such as cardiovascular disease and cancer, will enhance participants’ ability to choose treatments. New antipsychotic medications and treatment augmentation will be reviewed along with potential new uses for mood stabilizers. Updates on the latest treatment of anxiety disorders, use of benzodiazepines, and PTSD will be highlighted.

Neurobiologic mechanisms of depression, with discussion of the role of inflammation, will be emphasized. Updates on evidence-based use of antidepressants will incorporate the latest clinical findings. Special consideration will be given to ketamine, ECT, TMS, psychedelics, and augmentation strategies for difficult-to-treat depression and bipolar depression.

An emphasis will be placed on special and unique populations for which medications are frequently prescribed. The second day will lead off with a review of the role of psychopharmacology in the treatment of sleep disorders. Latest advances in child, adolescent and geriatric psychopharmacology will be reviewed in two separate presentations. The use of medication across women’s reproductive life span will address such considerations as PMDD, pregnancy, lactation, and post-partum depression. A presentation on the neurobiology and treatment of alcohol, opioids, cannabis, and other substance use disorders will be included. Throughout the course, discussion of the importance of the therapeutic alliance when prescribing psychotropic medications will be underscored.

A major highlight of the course is that there will be considerable opportunity for interaction with the presenters in question-and-answer panel discussions.

LEARNING OBJECTIVES

Upon completion of this course, participants will be able to:

l Describe lessons learned from genomic sequencing of patients with psychiatric illnesses;

l Identify unsolved problems regarding the pharmacologic treatment of schizophrenia and learning more effective treatments;

l Describe emerging theories and treatments of bipolar disorder, difficult-to-treat depression, bipolar depression, and anxiety disorder;

l Outline the perils and possibilities of psychedelics and ketamine;

l Recognize when to utilize ECT and TMS for treatment-resistant depression;

l Illustrate emerging treatments for PTSD;

l Review sleep disorders commonly comorbid with psychiatric illness, and appropriate use of medications and treatment;

l Review interface of medicine and psychiatry with a focus on cancer, cardiovascular disease;

l Review the interface of neurology and psychiatry with an emphasis on functional neurological disease, hysteria, movement disorders, pain, OCD and others;

l Summarize the use of genetic tests, serum level measurements, and drug combinations in treatment-resistant depression;

l Identify the current role of pharmacotherapy in the treatment of substance use disorders including alcohol, opioids, and cannabis;

l Review the role of pharmacotherapy in the treatment of psychiatric disorders throughout women’s reproductive lifespan, with a focus on the premenstrual, prenatal, postpartum, and perimenopausal periods;

l Examine the latest advances and problems associated with treatment approaches in the child, adolescent, and geriatric populations.

COURSE SCHEDULE FRIDAY | MARCH 31, 2023

7:45 a.m.–8:15 a.m. Registration

8:15 a.m.–8:30 a.m. Welcome Remarks

Barbara Coffey, M.D., M.S. and Charles Nemeroff, M.D., Ph.D.

8:30 a.m.–9:15 a.m. Lessons Learned from the DNA of Patients with Psychiatric Illness Daniel Weinberger, M.D.

9:15 a.m.–10:00 a.m. Neuropsychiatry: Interface between Neurological and Psychiatric Disorders Martin Samuels, M.D., D.Sc. (hon)

10:00 a.m.–10:30 a.m. Coffee break

10:30 a.m.–11:15 a.m. Interface of Medical and Psychiatric Disorders with an Emphasis on Cardiovascular Disease and Cancer Charles Nemeroff, M.D., Ph.D.

11:15 a.m.–12:00 p.m. Tackling Unsolved Problems in the Pharmacological Treatment of Schizophrenia: Cognitive Impairment, Negative Symptoms, and Partial Treatment Response Philip Harvey, Ph.D.

12:00 p.m.–12:45 p.m. Panel Discussion

Philip Harvey, Ph.D., Charles Nemeroff, M.D., Ph.D., Martin Samuels, M.D., D.Sc. (hon), Daniel Weinberger, M.D.

12:45 p.m.–2:00 p.m. Lunch

2:00 p.m.–2:45 p.m. Latest Advances and Current Treatment of Bipolar Mania and Bipolar Depression Ross Baldessarini, M.D., D.Sc. (hon)

2:45 p.m.–3:30 p.m. Benzodiazepines: Risks and Benefits David Sheehan, M.D., M.B.A.

3:30 p.m.–3:45 p.m. Coffee break

3:45 p.m.–4:30 p.m. Post Traumatic Stress Disorders

Charles Nemeroff, M.D., Ph.D.

4:30 p.m.–5:30 p.m. Panel Discussion

Ross Baldessarini, M.D., D.Sc. (hon), Charles Nemeroff, M.D., Ph.D., David Sheehan, M.D., M.B.A.

5:30 p.m. Adjourn

COURSE SCHEDULE SATURDAY | APRIL 1, 2023

8:15 a.m. Welcome and Overview

Barbara Coffey, M.D., M.S.

8:30 a.m.–9:15 a.m. Clinical Use of Psychotropic Drugs for the Treatment of Sleep Disorders Sogol Javaheri, M.D.

9:15 a.m.–10:00 a.m. Treatment-Resistant Depression

Stephen Stahl, M.D., Ph.D., D.Sc. (hon)

10:00 a.m.–10:30 a.m. Coffee Break

10:30 a.m.–11:15 a.m. Psychedelics and Ketamine

Alan Schatzberg, M.D.

11:15 a.m.–12:00 p.m. Pharmacological Treatment of Substance Use Disorders: Alcohol, Opioids, and Cannabis Roger Weiss, M.D.

12:00 p.m.–12:45 p.m. Panel Discussion

Barbara Coffey, M.D., M.S., Sogol Javaheri, M.D., Alan Schatzberg, M.D., Stephen Stahl, M.D., Ph.D., D.Sc. (hon), Roger Weiss, M.D.

12:45 p.m.–2:00 p.m. Lunch

2:00 p.m.–2:45 p.m. Child and Adolescent Psychopharmacology: Current Treatment for Best Practices Barbara Coffey, M.D., M.S.

2:45 p.m.–3:30 p.m. Psychopharmacology Across the Reproductive Lifespan: From Menarche to Menopause Ariadna Forray, M.D.

3:30 p.m.–3:45 p.m. Coffee break

3:45 p.m.–4:30 p.m. Geriatric Psychopharmacology

Elizabeth Crocco, M.D.

4:30 p.m.–5:30 p.m. Panel Discussion

Barbara Coffey, M.D., M.S., Elizabeth Crocco, M.D., Ariadna Forray, M.D.

5:30 p.m. Adjourn

Ross Baldessarini, M.D., D.Sc. (hon) Professor of Psychiatry and Neuroscience, Harvard Medical School; Director of the Psychopharmacology Program and International Consortium for Mood & Psychotic Disorder Research at McLean Hospital; Author of nearly 3,300 scientific publications and several books, including Chemotherapy in Psychiatry, and for several decades, the chapters on psychopharmacology in the standard American textbook of pharmacology, Goodman and Gilman’s The Pharmacological Basis of Therapeutics; Member of editorial boards of several leading clinical and neuroscience journals.

Barbara Coffey, M.D., M.S. Professor and Chair of the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine; Chief of the Division of Child and Adolescent Psychiatry; Associate Editor, Journal of Child and Adolescent Psychopharmacology; Author of more than 150 manuscripts in peerreviewed journals, abstracts, and book chapters.

Elizabeth Crocco, M.D. Clinical Professor, Chief of Geriatric Psychiatry, Department of Psychiatry and Behavioral Sciences at the University of Miami (UM) Miller School of Medicine; Medical Director, UM Memory Disorders Clinic, Center for Cognitive Neuroscience & Aging (CNSA); Geriatric Psychiatry Training Director, UM/Jackson Memorial Hospital; Author of numerous publications and book chapters and clinical research contributions within the scientific field of Geriatric Psychiatry, including Alzheimer’s and related dementias, late-life depression, cognition and geriatric psychopharmacology. She also directly facilitates the primary training and supervision of all geriatric psychiatry fellows, psychiatry residents, medical students at UM and other physicians/health care professionals in the field.

Ariadna Forray, M.D. Associate Professor of Psychiatry, interim Section Chief of Psychological Medicine, and Director of the Center for the Wellbeing of Women and Mothers at Yale School of Medicine; board member of the North American Society of Psychosocial Obstetrics and Gynecology; author of numerous publications and book chapters on reproductive psychiatry, including Antidepressant Use in Perinatal Depression, Psychiatry 4th Edition.

Philip Harvey, Ph.D. Leonard M. Miller Professor of Psychiatry, Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine; VA Senior Health Scientist; Recipient of first Schizophrenia International Research Society Clinical Scientist Distinguished Contributions award in 2012, the Alexander Gralnick Schizophrenia Research award from the American Psychiatric Foundation, the Department of Veterans affairs John Blair Barnwell award, and the Stanley Dean Award from the American College of Psychiatrists; Author of over 1,000 scientific papers and 60 book chapters; Editor-in-Chief, Schizophrenia Research: Cognition

Sogol Javaheri, M.D. Instructor in Medicine, Harvard Medical School; Associate Program Director, Sleep Medicine Fellowship, Brigham and Women’s Hospital.

Charles Nemeroff, M.D., Ph.D. Matthew P. Nemeroff Professor and Chair Department of Psychiatry and Behavioral Sciences; Mulva Clinic for the Neurosciences;

Director, Institute of Early Life Adversity Research, Dell Medical School, The University of Texas at Austin; past Leonard M. Miller Professor and Chairman, Department of Psychiatry and Behavioral Sciences, the University of Miami Miller School of Medicine; President, Anxiety and Depression Association of America; past President of the American College of Psychiatrists, International Society of Psychoneuroendocrinology and the American College of Neuropsychopharmacology; member of the National Academy of Medicine; author of over 1,200 scientific articles and book chapters; Co-editor, Textbook of Psychopharmacology; Co-editor, Post Traumatic Stress Disorder.

Martin Samuels, M.D., D.Sc. (hon) Founding Chair, Department of Neurology, Brigham and Women’s Hospital; Miriam Sydney Joseph Professor of Neurology, Harvard Medical School; recipient of Harvard’s first Faculty Prize for Excellence in Teaching; 2006 recipient of the AB Baker Award for Lifetime Achievement in Neurologic Education; Founding Editor of NEJM Journal Watch Neurology, Editor-in-Chief 1999-2010; Fellow of the American Academy of Neurology, Master of the American College of Physicians; past president of the Association of University Professors of Neurology; Creator of Samuels’s Manual of Neurologic Therapeutics.

Alan Schatzberg, M.D. Kenneth Norris Jr. Professor, Department of Psychiatry and Behavioral Sciences, Stanford University; past Chair of Psychiatry, Stanford University School of Medicine; Past-President, American Psychiatric Association; Editorial board of many journals; Author of over 600 publications; Co-author, Manual of Clinical Psychopharmacology; Co-editor of Textbook of Psychopharmacology.

David Sheehan, M.D., M.B.A. Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine, where he was Director of the Depression and Anxiety Disorders Research Institute and Professor of Psychiatry; past consultant to the World Health Organization and the U.S. Food & Drug Administration; Author of over 500 abstracts and 300 publications, 11 books/monographs.

Stephen Stahl, M.D., Ph.D., D.Sc. (hon) Professor of Psychiatry, University of California, San Diego; Honorary Visiting Senior Fellow, University of Cambridge, UK; recipient of many national and international awards; Author of over 500 publications; Author of 53 books including Essential Psychopharmacology and Prescriber’s Guide; Editor of 15 books; Editorial board of several journals including Editor-in-Chief, CNS Spectrums.

Daniel Weinberger, M.D. Professor of Psychiatry, Neurology, Neuroscience and Genetic Medicine, Johns Hopkins University; Director and CEO of the Lieber Institute for Brain Development; recipient of many honors and awards; Member of the National Academy of Medicine; Author of over 700 papers; Author/editor of 11 books.

Roger Weiss, M.D. Professor of Psychiatry, Harvard Medical School and Chief of the Division of Alcohol, Drugs, and Addiction at McLean Hospital. Author, over 400 scientific publications including, Integrated Group Therapy for Bipolar Disorder and Substance Abuse; Editorial board of many journals including American Journal of Drug and Alcohol Abuse, Journal of Clinical Psychiatry, and the American Journal on Addictions.

TARGET AUDIENCE

Practicing clinicians in the field of psychopharmacology drawn from the following disciplines: psychiatry, medicine, nursing, nurse practitioners, and psychology.

ABMS/ACGME COMPETENCIES

This course is designed to meet the following American Board of Medical Specialties (ABMS)/Accreditation Council for Graduate Medical Educational (ACGME) competencies: Medical knowledge

ACCREDITATION

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physician Credit: The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

European Accreditation: Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.

Physician Assistants: The National Commission on  Certification of Physician Assistants (NCCPA) states that AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification. We would also suggest that learners check with their state licensing board to ensure they accept reciprocity with AMA PRA Category 1 Credit™ for re-licensure.

Psychology Credit:  The University of Miami Leonard M. Miller School of Medicine is approved by the American Psychological Association (APA) to sponsor continuing education for psychologists. The University of Miami Leonard M. Miller School of Medicine maintains responsibility for this program and its content. 14.00 CE credits will be awarded to psychologists for attendance at this conference.

Nursing: Oakstone Publishing is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Contact Hours: 14.

ONLINE INFORMATION

To register or view activity information online, visit: https://bit.ly/3AEITMv

REGISTRATION INFORMATION

Tuition Fee: Physicians and other doctoral level registrants: early-bird rate is $895. After Jan. 20, 2023, registration fee is $995. Nurses, Master Level Professionals, Fellows, Residents and others: early-bird rate $695. After Jan. 20, 2023, registration fee is $795. *All fees shown in USD. Add processing fee (non-refundable) of $10. Registration by credit card (VISA, Mastercard or American Express), fax registration is not accepted.

Registration with cash payment is not permitted. Upon receipt of your paid registration, you will receive an email confirmation. Be sure to include an email address that you check frequently. Your email address is used for critical information including registration confirmation, evaluation, and certificate.

The tuition fee is the same if you attend virtually or in person at the Fairmont Copley Plaza. All course participants receive a link to a website where they can download all of the course materials. You can purchase a printed copy at the time of online registration for $60 (in-person attendees only; we cannot ship course materials). Please note we will not have hard copies of the syllabus available for purchase at the conference. Register online: https://bit.ly/3AEITMv

INQUIRIES

Please email Kim Miele at kpm99@miami.edu or call 941.932.2671, 10 a.m.–4 p.m. (EST) Monday-Friday.

DISCLOSURE AND CONFLICT OF INTEREST MITIGATION

The University of Miami Leonard M. Miller School of Medicine has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. The University of Miami Leonard M. Miller School of Medicine planners, content reviewers, and editorial staff disclose no relationships with ineligible entities. All the relevant financial relationships for these individuals have been mitigated.

SPECIAL REQUESTS

If special arrangements are required for an individual with a disability to attend this conference, contact Kim Miele at kpm99@miami.edu at least 15 days prior to the conference.

REFUND POLICY

Refunds, less an administrative fee of $75, will be issued for all cancellations received two weeks prior to the start of the course. Refund requests must be received by email. No refund will be issued should cancellation occur less than two weeks prior. “No-shows” are subject to the full course fee and no refunds will be issued once the conference has started.

COURSE LOCATION FOR IN-PERSON REGISTRANTS

The conference will be at the Fairmont Copley Plaza, 138 St. James Ave., Boston, Mass. (Phone: 617.267.5300)

ACCOMMODATIONS/TRAVEL

In keeping with public health recommendations, hotel occupancy in Boston may be restricted. The number of rooms reserved for attendees at the Fairmont Copley Plaza is limited. Please make your hotel reservation early. Call 617.267.5300 or 800.441.1414 for reservations before March 9, 2023, for the discounted group rate. Specify that you are with the University of Miami Miller School of Medicine Psychopharmacology course 2023. Please do not purchase non-refundable airline ticket(s) until you have received an email from our office confirming your paid registration.